Cell reprogramming specialist bit bio has expanded its management with renowned experts in the field.
Swiss biotech company BioVersys AG has received a €8m grant by US-based non-profit organisation CARB-X to develop novel anti-virulence antibiotics to treat severe bacterial infections.
A team of Japanese and German researchers has found the protein that helps activate the inflammasome following viral invasion.
Researchers at University Lyon have found a potential repurposing application of two market-approved rotavirus vaccines.
Swiss Polyphor AG and researchers from the University of Zurich have presented the mechanism of action of a new class of antibiotics.
Zealand Pharma A/S has acquired Encycle Therapeutics Inc, including a peptide therapeutics platform and library.
German researchers have found a novel way to induce iron-induced necrosis, a process which they want to turn against cancer.
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its October 2019 meeting.
A molecular transporter is critical for the proper maturation of neurons underlying neurodevelopmental disorders.
AI-driven drug repurposing company Healx Ltd (Cambridge, UK) raises US$56m in a Series B financing and launches global accelerator programme for orphan diseases.